Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Elan Pharmaceuticals |
---|---|
Information provided by: | Elan Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00076544 |
The purpose of this open-label study is to give chronic severe pain patients with existing intrathecal pump systems access to ziconotide.
Condition | Intervention | Phase |
---|---|---|
Pain |
Drug: Ziconotide |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Safety Study |
Official Title: | An Open-Label, Long-Term, Multi-Center, Intrathecal Ziconotide (PRIALT) Effectiveness and Safety Trial (ZEST) in Patients With Chronic Severe Pain |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | ELN92045-501 |
Study First Received: | January 26, 2004 |
Last Updated: | February 2, 2007 |
ClinicalTrials.gov Identifier: | NCT00076544 |
Health Authority: | United States: Food and Drug Administration |
Intrathecal |
Calcium, Dietary Ziconotide Pain |
Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Calcium Channel Blockers Cardiovascular Agents Neuroprotective Agents Protective Agents Pharmacologic Actions |
Membrane Transport Modulators Analgesics, Non-Narcotic Sensory System Agents Therapeutic Uses Peripheral Nervous System Agents Analgesics Central Nervous System Agents |